Showing 8161-8170 of 8822 results for "".
- GMC, RCS Raise the Bar for Cosmetic Surgery in the UKhttps://practicaldermatology.com/news/gmc-rcs-raise-the-bar-for-cosmetic-surgery-in-the-uk/2458611/Starting in June 2016, the UK will have new rules and regulations governing the practice of cosmetic surgery and the practices of cosmetic surgeons. The new guidance, issued by the General Medical Council (GMC), aims to reign in cosmetic cowboys in the
- Avalere: Biosimilars More Expensive for Medicare Beneficiarieshttps://practicaldermatology.com/news/avalere-biosimilars-more-expensive-for-medicare-beneficiaries/2458610/Medicare beneficiaries are likely to pay more for biosimilars than for the biologic reference product in Part D under current law, according to a new report from
- Alphaeon's Botulinum Toxin Meets Primary Endpoints in Two Phase III Trialshttps://practicaldermatology.com/news/alphaeons-botulinum-toxin-meets-primary-endpoints-in-two-phase-iii-trials/2458615/Alphaeon’s DWP-450 botulinum toxin type A achieved it primary endpoints in two Phase III trials reported at the American Society of Aesthetic Plastic Surgery meeting in Las Vegas. In the two phase III randomized, multi-center, placebo-controlled, double blind tria
- Pfizer-AGN Deal Offhttps://practicaldermatology.com/news/all-eyes-on-pfizer-agn-deal-is-it-doa/2458617/UPDATE: Allergan and Pfizer have mutually agreed to end their merger agreement, according to a statement from Allergan. Pfizer has agreed to pay Allergan $150 million in reimbursement for expenses associated with the transaction. Dublin-based Allergan reiterates in the statement its growth opport
- New from Suneva: Regenica® Rejuvenating Dual Serumhttps://practicaldermatology.com/news/new-from-suneva-regenica-rejuvenating-dual-serum/2458620/Suneva Medical, Inc., is rolling out Regenica® Rejuvenating Dual Serum, the newest addition to the Regenica® skin care line. The dual chamber serum is created via growth factor
- Melanoma Cells Grow More Aggressive with Agehttps://practicaldermatology.com/news/melanoma-cells-grow-more-aggressive-with-age/2458622/Aged tumor cells in melanoma tend to be metastatic and more resistant to treatment compared with younger tumor cells, according to an international team led by researchers out of The Wistar Institute in Philadelphia. The findings, which appear in
- North America's Scar Treatment Poised for Growth Spurt by 2022https://practicaldermatology.com/news/north-america-scar-treatment-market-set-to-grow-by-2022/2458629/Scar treatment will be a hot growth area in coming years, according to a new report by Persistence Market Research. The report cites a rising incidence of burn and trauma cases and an increasing preval
- More Than 1,000 Patients Join Corrona Psoriasis Registryhttps://practicaldermatology.com/news/more-than-1000-patients-join-corrona-psoriasis-registry/2458631/The Corrona Psoriasis Registry, a joint collaboration between the National Psoriasis Foundation (NPF) and Corrona, LLC, now includes more than 1,000 patients from 100 sites. Dermatologists assess registry pa
- Take That, Melanoma! New Patch Delivers Anti-PD-1 Antibodies Directly to Skin Cancerhttps://practicaldermatology.com/news/take-that-melanoma-new-patch-delivers-anti-pd-1-antibodies-directly-to-skin-cancer/2458633/A new patch embedded with microneedles may deliver anti-PD-1 antibodies directly to the site of melanoma, according to a study in Nano Letters. In animal studies, the technique more effectively targeted
- FDA Greenlights Taltz for Psoriasishttps://practicaldermatology.com/news/fda-greenlights-taltz-for-psoriasis/2458635/The U.S. Food and Drug Administration approved the IL-17A blocker Taltz (ixekizumab) for adults with moderate-to-severe plaque psoriasis. Taltz is marketed by Indianapolis, Indiana-based Eli Lilly and Company. Given via